All News
The RheumNow Week in Review - 26 January 2018
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report covers the price of biologics treatment in psoriasis, comorbidities in myositis, bronchiectasis with MPO antibodies, and the risk of secondary TNF failure with anti-drug antibodies.
Read Article
Teriparatide Superior to Risedronate in the VERO Trial
Lancet reports that in a study teriparatide with risedronate, post-menopausal women with severe osteoporosis had significantly fewer new vertebral and clinical fractures on teriparatide comared to those receiving risedronate.
Read ArticleCimzia Limits Xray Progression in Axial Spondyloarthritis
The RAPID-axSpA study of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) patients showed that certolizumab pegol (CZP) treatment yielded rapid clinical improvement with limited radiographic progression and MRI inflammation at the sacroiliiac (SI) joint over 4 years.
Read Article
Two Types of Osteoarthritis Based on Cartilage Studies
A report from Annals of Rheumatic Diseases suggests that osteoarthritis (OA) may be two distinct diseases based on genetic studies of articular cartilage. (Citation source: https://buff.ly/2mNtUsL).
Read Article
Bone Marrow Edema May be Found in Normals, Athletes and Military Recruits
Rheumatology has published a study demonstrating that bone marrow edema as measured by magnetic resonance imaging (MRI) may be found in healthy people, but that such changes do not change with intense physical activity.
Read Article
Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA (Best of 2017)
In this Therapeutic Update, Drs. Mease, Gibofsky and Cush answer five questions regarding the August 3rd FDA Arthritis Advisory Committee meeting that reviewed the potential approval of tofacitinib (Xeljanz) in patients with active psoriatic arthritis. The panel was nearly unanimous (10-1) in favor of the efficacy and safety profile of of tofacitinib, and similarly voted 10-1 to approve this drug for use in PsA. Final decisions on these recommendations from the AAC panel will be made at a later date by the FDA.
Read Article
Febuxostat Works in Early Gout But Fails to Protect from Xray Damage
Dalbeth and colleagues have published a novel report in Arthritis & Rheumatology, novel in that it is a trial of early gout patients that looks at clinical and radiographic outcomes. They showed that febuxostat improves magnetic resonance imaging (MRI) measures of synovitis and reduced gout flares, but failed to alter X-ray progression with 2 years follow-up.
Read Article
Good News from ACR17 - Gout
The following is a collection of gout-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.
Read Article
Several Agents Score on Radiographic Progression in Psoriatic Arthritis
Reduction on radiographic progression has now become the standard of care in the therapies used to treat psoriatic arthritis and, during the 2017 ACR Meeting, several agents reported the results of their studies with radiographic endpoints.
Read Article
Key Takeaways from ACR Review Course
The ACR Review Course was superb once again from top to bottom, from Blue Fingers to Practical Treatment of RA. Every year I wonder if I should skip it, but each year I go. And I have never regretted it. Here are my take-home messages and “pearls” from the ACR Review Course.
Read Article
Spinal X-ray Inhibition in Ankylosing Spondylitis Best Achieved by Control of Activity
Although tumour necrosis factor inhibitors (TNFi) are highly effective (on clinical grounds) in ankylosing spondylitis (AS), proof that they may alter the course of spinal radiographic progression has been scant.
Read Article
The RheumNow Week in Review - 6 October 2017
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.
Read Article
Osteoporotic Fractures as Back Pain in Older Men
The Journal of Bone and Mineral Research reports that older men with undiagnosed vertebral fractures are likely to report new or worsening back pain. (Citation source bit.ly/2y9rMiZ)
Read Article
New EULAR Guidelines for Ultrasound Use
In the current issue of ARD, the European League Against Rheumatism (EULAR) has revised and updated its 2001 guideline for musculoskeletal (MS) ultrasound (US) in rheumatology; this time incorporating new advances, technological developments and use indications in rheumatology. EULAR has provided this as an educational tool and standard reference for MSUS practice and research in rheumatology.
Read Article
Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA
In this Therapeutic Update, Drs. Mease, Gibofsky and Cush answer five questions regarding the August 3rd FDA Arthritis Advisory Committee meeting that reviewed the potential approval of tofacitinib (Xeljanz) in patients with active psoriatic arthritis. The panel was nearly unanimous (10-1) in favor of the efficacy and safety profile of of tofacitinib, and similarly voted 10-1 to approve this drug for use in PsA. Final decisions on these recommendations from the AAC panel will be made at a later date by the FDA.
Read Article
MSK Ultrasound Now Standard for Rheumatology Training
In the United States, musculoskeletal ultrasound (MSUS) in rheumatology has grown significantly in the last few decades. Ten years ago, more than half of rheumatology fellows had training or exposure to MSUS. A current survey of training programs shows that 94% provide MSUS training.
Read Article
Romosuzumab Outperforms Teriparatide in Post-Bisphosphonate Osteoporosis
The STRUCTURE trial results have been reported in Lancet and have shown that after 12 months of therapy, romosozumab (ROMO) had superior gains in bone mineral density (BMD) compared to teriparatide (TER) in women with postmenopausal osteoporosis who have previously taken bisphosphonate therapy.
Read Article
The RheumNow Week in Review – 28 July 2017
Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com:
Read Article
Alveolar Hemorrhage in Lupus Needs Prompt Evaluation
Acute diffuse lung infiltration in patients with systemic lupus erythematosus (SLE) requires prompt evaluation for diffuse alveolar hemorrhage (DAH) when patients have low levels of hemoglobin and complement compound C4 and symptoms of hypoxia.
Read Article
Higher Fracture Risks with Prolonged Bisphosphonate Use in Older Women
The Journal of the American Geriatric Society has reported that older women receiving bisphosphonate therapy for greater than 10-13 years were more likely to suffer from fractures.
Read Article